Objective:
The article examines the objective, findings, and clinical context described in FDA approves gefurulimab for myasthenia gravis.
Approach:
- Approval and mechanism: The FDA approved gefurulimab-gaks (Klygefa), a complement C5 inhibitor, for adults with AChR antibody-positive generalized myasthenia gravis. It is administered subcutaneously once weekly.
- Evidence: Approval was supported by PREVAIL, a 26-week, randomized, double-blind, placebo-controlled phase 3 trial of 260 adults who continued eligible background therapies at stable doses.
- Administration and safety requirements: The weight-based regimen begins with a loading dose on day 1, followed by weekly dosing from day 8. The label includes a boxed warning for serious meningococcal infections and requires vaccination and participation in a restricted REMS.
Key Findings:
- At week 26, MG-ADL scores improved by 4.2 points with gefurulimab and 2.6 points with placebo; the treatment difference was −1.6 points.
- Quantitative Myasthenia Gravis scores improved by 4.5 points with gefurulimab and 2.4 points with placebo.
- At least a 3-point MG-ADL improvement occurred in 65.5% of gefurulimab recipients and 52.2% of placebo recipients.
- Reported adverse events included injection-site reactions (12% vs 3%), back pain (8% vs 2%), and vomiting (5% vs 1%) with gefurulimab versus placebo, respectively.
Interpretation:
The FDA-approved prescribing information identifies change from baseline in MG-ADL score at week 26 as the primary endpoint. AstraZeneca reported that improvements began at week 1 and continued through week 26.
Limitations:
- The provided context does not report longer-term outcomes beyond the 26-week trial.
- The provided context does not include detailed results for other safety outcomes.
Conclusion:
Patients or caregivers may administer gefurulimab after appropriate training. The label requires meningococcal vaccination at least 2 weeks before treatment; antibacterial prophylaxis is required when urgent treatment is needed in patients not up to date with vaccination. Treatment must not be initiated during an unresolved serious Neisseria meningitidis infection.
Sources:
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
